Filing Analysis
Cognition Therapeutics reported the results of its Annual Meeting of Stockholders held on June 17, 2026. The stockholders elected two Class II directors and ratified the appointment of Ernst & Young LLP as the independent auditor for the 2026 fiscal year.
📋 Key Facts
- Annual Meeting of Stockholders held virtually on June 17, 2026.
- Aaron Fletcher, Ph.D. and Lisa Ricciardi were elected as Class II directors to serve until the 2029 Annual Meeting.
- Ernst & Young LLP was ratified as the independent registered public accounting firm for the 2026 fiscal year.
- Voting for auditor ratification: 49,039,407 For, 126,951 Against, and 643,517 Abstentions.
Cognition Therapeutics, Inc. filed an 8-K to furnish an investor presentation under Regulation FD. The filing serves as a formal disclosure of materials the company may use in discussions with investors and analysts.
📋 Key Facts
- The filing date is June 4, 2026.
- The company furnished an investor presentation as Exhibit 99.1.
- The information is provided solely to satisfy Regulation FD requirements and is not deemed 'filed' under Section 18 of the Exchange Act.
Cognition Therapeutics, Inc. announced the completion of its meeting with the U.S. Food and Drug Administration (FDA) regarding zervimesine for dementia with Lewy bodies patients with psychosis.
📋 Key Facts
- The company filed an Item 8.01 (Other Events) 8-K on May 21, 2026.
- The filing announces the completion of a meeting with the FDA.
- The meeting focused on the development of zervimesine for dementia with Lewy bodies patients with psychosis.
- A press release detailing the meeting was filed as Exhibit 99.1.
Cognition Therapeutics, Inc. announced its financial results for the first quarter ended March 31, 2026. The announcement was made via a press release furnished as an exhibit to the 8-K filing.
📋 Key Facts
- The filing reports financial results for the fiscal quarter ended March 31, 2026.
- The report was filed under Item 2.02 (Results of Operations and Financial Condition).
- The press release was issued on May 7, 2026, and is included as Exhibit 99.1.
- The company is classified as an emerging growth company.
Cognition Therapeutics announced its financial results for the fiscal year ended December 31, 2025, and furnished an updated investor presentation.
📋 Key Facts
- The company reported financial results for the year ended December 31, 2025, on March 26, 2026.
- Furnished Exhibit 99.1: Press Release regarding financial results.
- Furnished Exhibit 99.2: Updated investor presentation for discussions with analysts and investors.
- The company maintains its status as an emerging growth company.
Cognition Therapeutics announced plans to advance the development of its drug candidate, zervimesine, for the treatment of dementia with Lewy bodies (DLB) psychosis. The announcement was made via a press release on March 2, 2026.
📋 Key Facts
- The company is advancing zervimesine for the treatment of dementia with Lewy bodies (DLB) psychosis.
- The announcement was filed under Item 8.01 (Other Events) on March 2, 2026.
- Cognition Therapeutics is classified as an emerging growth company.